PharmaForceIQ is reshaping pharmaceutical marketing by moving beyond traditional omnichannel strategies into optichannel engagement—a real-time, data-driven approach that ensures the right message reaches the right healthcare professional (HCP) or patient at the exact moment of opportunity.
This interview with Rare Revolution Insider highlights how AI-powered, real-time precision marketing is not just improving engagement metrics—it’s transforming patient outcomes in rare diseases. For pharma marketers, it’s a blueprint for smarter, more cost-efficient campaigns in a space where every patient opportunity counts.
“Hemal firmly believes the optichannel strategy is poised to become an essential standard in rare disease and specialised medicine. ‘I see this being a gold standard for all rare disease launches, because each and every launch has the same problem to solve in the rare space. Resources are tight. Our field force presence is limited and we have these very rare patient opportunities being presented across this massive list of HCPs that we can go after. So how do we get smarter, better and more cost efficient? Our optichannel approach allows you to do that across general, specialist and rare medicine.’ ”
Please note: This is gated content. You will need to create an account to access it.